Ticker Details
VistaGen Therapeutics, Inc. VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
IPO Date:	July 1, 2011
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$22.19M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.09 | 4.04%
Avg Daily Range (30 D):	$0.03 | 4.35%
Avg Daily Range (90 D):	$0.11 | 4.14%

Institutional Daily Volume
Avg Daily Volume:	.66M
Avg Daily Volume (30 D):	.98M
Avg Daily Volume (90 D):	1.78M

Trade Size
Avg Trade Size (Sh.):	202
Avg Trade Size (Sh.) (30 D):	377
Avg Trade Size (Sh.) (90 D):	330

Institutional Trades
Total Institutional Trades:	84
Avg Institutional Trade:	$2.29M
Avg Institutional Trade (30 D):	$.59M
Avg Institutional Trade (90 D):	$1.93M
Avg Institutional Trade Volume:	.22M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.82M
Avg Closing Trade (30 D):	$.76M
Avg Closing Trade (90 D):	$.76M
Avg Closing Volume:	147.97K

News

Feb 24, 2026 @ 8:51 PM INVESTOR ALERT: Pomerantz Law Firm Reminds Investo... Source: Pomerantz Llp

Feb 24, 2026 @ 1:00 PM Holzer & Holzer, LLC Reminds VTGN Investors of the... Source: Holzer & Holzer, Llc

Feb 23, 2026 @ 10:46 PM ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistage... Source: Rosen Law Firm

Feb 23, 2026 @ 5:00 PM Bronstein, Gewirtz & Grossman LLC Urges Vistagen T... Source: Bronstein, Gewirtz & Grossman Llc

Feb 21, 2026 @ 5:35 PM Bragar Eagel & Squire, P.C. Reminds Investors That... Source: Bragar Eagel & Squire, P.C.

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.45	$-.54	$-.47
Diluted EPS	$-.45	$-.54	$-.47
Revenue	$.3M	$.26M	$.24M
Gross Profit
Net Income / Loss	$-18.9M	$-19.42M	$-15.1M
Operating Income / Loss	$-19.55M	$-20.05M	$-15.8M
Cost of Revenue
Net Cash Flow	$-15.42M	$13.8M	$-18.15M
PE Ratio

Splits
Jun 07, 2023	1:30
Aug 14, 2014	1:20
Jun 10, 2011	2:1